Fracture prevention in postmenopausal women
Substantive changes at this update
Pamidronate Evidence reassessed. Categorised as Unknown effectiveness (as RCT evidence found was not of sufficient quality to assess its effects).
Calcium alone New evidence added to harms section. Categorisation changed (from Unlikely to be beneficial to Likely to be ineffective or harmful).
Calcium plus vitamin D New evidence added. Categorisation unchanged (Likely to be beneficial).
Exercise New evidence added. Categorisation unchanged (Unknown effectiveness), as there remains insufficient evidence to judge the effects of this intervention in postmenopausal women.
Hip protectors New evidence added. Categorisation unchanged (Likely to be beneficial).
INTRODUCTION: The lifetime risk of fracture in white women is 20% for the spine, 15% for the wrist, and 18% for the hip, with an exponential increase in risk beyond the age of 50 years. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of bisphosphonates to prevent fractures in postmenopausal women? What are the effects of pharmacological treatments other than bisphosphonates to prevent fractures in postmenopausal women? What are the effects of non-pharmacological treatments to prevent fractures in postmenopausal women? We searched: Medline, Embase, The Cochrane Library, and other important databases up to September 2010 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found 71 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: alendronate, calcium, calcium plus vitamin D, clodronate, denosumab, etidronate, exercise, hip protectors, hormone replacement therapy, ibandronate, multifactorial non-pharmacological interventions, pamidronate, parathyroid hormone, raloxifene, risedronate, strontium ranelate, vitamin D, vitamin D analogues, and zoledronate.dfsg
Rated by doctors in Relevance Newsworthiness General Practice(GP)/Family Practice(FP) ***** ****** General Internal Medicine-Primary Care(US) ***** ******
Rated by doctors in Relevance Newsworthiness General Practice(GP)/Family Practice(FP) ****** ***** General Internal Medicine-Primary Care(US) ****** ***** Endocrine ****** ***** Gynecology ***** ****